Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease

Scientific World Journal

Volumn 2015, Issue , 2015, Pages

  Zanoli, L ^a   Granata, A ^b   Lentini, P ^c   Rastelli, S ^a   Fatuzzo, P ^a   Rapisarda, F ^a   Castellino, P ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Department of Nephrology Presidio Ospedaliero Agrigento ^*  (Italy)

^c San Bassiano Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCOSE; INSULIN; METFORMIN; PIOGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; URIC ACID; VILDAGLIPTIN; 1,5-ANHYDRO-1-(5-(4-ETHOXYBENZYL)-2-METHOXY-4-METHYLPHENYL)-1-THIOGLUCITOL; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN; SORBITOL;

ANTIDIABETIC ACTIVITY; BLADDER CANCER; BLOOD PRESSURE REGULATION; BREAST CANCER; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DEHYDRATION; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; HYPOTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANIMALS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; SORBITOL;

EID: 84924259775     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2015/317507     Document Type: Review

References (33)

1. D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, "IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030," Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 311-321, 2011.
2. R. N. Foley and A. J. Collins, "End-stage renal disease in the United States: an update from the United States Renal Data System," Journal of the American Society of Nephrology, vol. 18, no. 10, pp. 2644-2648, 2007.
3. G. Coll-De-Tuero, M. Mata-Cases, A. Rodriguez-Poncelas et al., "Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a randomsample of 2642 patients of a Mediterranean area," BMC Nephrology, vol. 13, no. 1, article 87, 2012.
4. C. E. Koro, B. H. Lee, and S. J. Bowlin, "Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States," Clinical Therapeutics, vol. 31, no. 11, pp. 2608-2617, 2009.
5. UKPDS 34, "Effect of intensive blood-glucose control withmetformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group," The Lancet, vol. 352, pp. 854-865, 1998.
6. "Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group," The Lancet, vol. 352, no. 9131, pp. 352-837, 1998.
7. D. E. Kohan, P. Fioretto,W. Tang, and J.F. List, "Long-termstudy of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control," Kidney International, vol. 85, no. 4, pp. 962-971, 2014.
8. J.-F. Yale, G. Bakris, B. Cariou et al., "Efficacy and safety of canagliflozin in subjectswith type 2 diabetes and chronic kidney disease," Diabetes, Obesity and Metabolism, vol. 15, no. 5, pp. 463-473, 2013.
9. J. F. Yale, G. Bakris, B. Cariou et al., "Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease," Diabetes, Obesity and Metabolism, vol. 16, no. 10, pp. 1016-1027, 2014.
10. A. H. Barnett, A. Mithal, J. Manassie et al., "Empagliflozin in patientswithtype 2 diabetesmellitus (T2DM) andrenal impairment (RI)," Diabetes, vol. 62, supplement 1, article 1104, 2013.
11. Y. Kanai,W.-S. Lee, G. You, D. Brown, and M. A. Hediger, "The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for Dglucose," The Journal of Clinical Investigation, vol. 93, no. 1, pp. 397-404, 1994.
12. V. Vallon, K. A. Platt, R. Cunard et al., "SGLT2 mediates glucose reabsorption in the early proximal tubule," Journal of the American Society of Nephrology, vol. 22, no. 1, pp. 104-112, 2011.
13. J. Calado, R. Santer, and J. Rueff, "Effect of kidney disease on glucose handling (including genetic defects)," Kidney International, vol. 79, pp. S7-S13, 2011.
14. E.M.Wright, D. D. F. L. Loo, and B. A. Hirayama, "Biology of human sodiumglucose transporters," Physiological Reviews, vol. 91, no. 2, pp. 733-794, 2011.
15. M. A. Abdul-Ghani, L. Norton, and R. A. DeFronzo, "Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes," Endocrine Reviews, vol. 32, no. 4, pp. 515-531, 2011.
16. K. Morrisey, R. Steadman, J. D. Williams, and A. O. Phillips, "Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent," Kidney International, vol. 55, no. 1, pp. 160-167, 1999.
17. U. Panchapakesan, K. Pegg, S. Gross et al., "Effects of SGLT2 inhibition in human kidney proximal tubular cellsrenoprotection in diabetic nephropathy?" PLoS ONE, vol. 8, no. 2, Article ID e54442, 2013.
18. D. Z. I. Cherney, B. A. Perkins, N. Soleymanlou et al., "Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus," Circulation, vol. 129, no. 5, pp. 587-597, 2014.
19. S. Engeli, J. Böhnke, K. Gorzelniak et al., "Weight loss and the renin-angiotensin-aldosterone system," Hypertension, vol. 45, no. 3, pp. 356-362, 2005.
20. C. Clar, J. A. Gill, R. Court, and N.Waugh, "Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes," BMJ Open, vol. 2, no. 5,Article ID e001007, 2012.
21. G. Musso, R. Gambino, M. Cassader, and G. Pagano, "A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials," Annals ofMedicine, vol. 44, no. 4, pp. 375-393, 2012.
22. D. Vasilakou, T. Karagiannis, E. Athanasiadou et al., "Sodiumglucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review andmeta-analysis," Annals of InternalMedicine, vol. 159, no. 4, pp. 262-274, 2013.
23. S. C. Thomson, T. Rieg, C. Miracle et al., "Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat," The American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 302, no. 1, pp. R75-R83, 2012.
24. J. Calado, Y. Sznajer, D. Metzger et al., "Twenty-one additional cases of familial renal glucosuria: Absence of genetic heterogeneity, high prevalence of privatemutations and further evidence of volume depletion," Nephrology Dialysis Transplantation, vol. 23, no. 12, pp. 3874-3879, 2008.
25. N. Kojima, J. M. Williams, T. Takahashi, N. Miyata, and R. J. Roman, "Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats," Journal of Pharmacology and Experimental Therapeutics, vol. 345, no. 3, pp. 464-472, 2013.
26. N. Nakamura, S. Masuda, K. Takahashi, H. Saito, M. Okuda, and K.-I. Inui, "Decreased expression of glucose and peptide transporters in rat remnant kidney," DrugMetab Pharmacokinet, vol. 19, no. 1, pp. 41-47, 2004.
27. M. Gangadharan Komala, S. Gross, H. Mudaliar et al., "Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice," PLoS ONE, vol. 9, no. 11, Article ID e108994, 2014.
28. N. Kojima, J. M. Williams, T. Takahashi, N. Miyata, and R. J. Roman, "Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats,"The Journal of Pharmacology and Experimental Therapeutics, vol. 345, no. 3, pp. 464-472, 2013.
29. R. E. Gilbert, "The perils of clinical trials," Kidney International, vol. 85, no. 4, pp. 745-747, 2014.
30. T. K. Burki, "FDA rejects novel diabetes drug over safety fears," The Lancet, vol. 379, no. 9815, article 507, 2012.
31. 2015, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMeta bolicDrugsAdvisoryCommittee/UCM334550.pdf
32. S. Anderson, H. G. Rennke, and B. M. Brenner, "Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat,"The Journal of Clinical Investigation, vol. 77, no. 6, pp. 1993-2000, 1986.
33. V. Vallon, M. Rose, M. Gerasimova et al., "Knockout of Naglucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus," American Journal of Physiology-Renal Physiology, vol. 304, no. 2, pp. F156-F167, 2013.